Skip to main content
Premium Trial:

Request an Annual Quote

Episona's Seed

Episona has launched its male fertility test, Seed. The test is the first of its kind on the market, and measures epigenetic changes in DNA to predict the risk for male factor infertility and poor embryo development. According to the company, while male factors contribute to about half of the cases of infertility in couples, testing options for men have been lacking.

A laboratory-developed test, Seed has a turnaround time of about two weeks. Physicians receive a detailed report on patients' likelihood of contributing to infertility and poor embryo development. This information can then help both the physician and patient understand whether a couple should spend time and money pursuing less invasive procedures such as intrauterine insemination or move directly to in vitro fertilization. By detecting issues that could impact sperm’s role in embryo development, Seed results can also help identify problems that might occur with IVF and provide answers if an IVF cycle fails, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.